---
title: "Ventfort"
canonical_url: https://peptidelibrary.app/library/ventfort
description: "Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Ventfort

Ventfort (also called Vessel bioregulator) is a khavinson vascular bioregulator. Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support.

Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved.

Also known as: Vessel bioregulator.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Khavinson vascular bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support. It is a complex of low-molecular-weight peptides rather than a single defined compound, so no specific sequence, receptor or downstream pathway can be identified, and it is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. The proposed mechanism is the series hypothesis that tissue-derived peptides influence transcription in the corresponding tissue, with claimed effects on endothelial protein synthesis. Evidence is historical, regional and uncontrolled.

Targets: Endothelium (proposed).

Origin: Peptide preparation from vascular tissue (per its description).

## Properties

- Sequence: Peptide complex A-3 (mixture; sequence not defined)
- Half-life: Not established in humans

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Adv Gerontol. 2014. 2014. Human study (early or uncontrolled). Population: Patients with vasculogenic erectile dysfunction linked to atherosclerosis (n=41). Better blood flow in the main penile arteries after vesugen alone, by clinical and instrument measures. Research on a related compound, not this one. Limitations: Studied an analog, not Ventfort itself [Source](https://pubmed.ncbi.nlm.nih.gov/25051774/)

## Safety

Side effects: Not characterized.

Risks: Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Ventfort is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Ventfort?

Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved.

### How does Ventfort work?

Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support. It is a complex of low-molecular-weight peptides rather than a single defined compound, so no specific sequence, receptor or downstream pathway can be identified, and it is distinct from Vesugen, the synthetic tripeptide associated with the same tissue.

### Is Ventfort FDA approved?

No. Ventfort is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Ventfort?

Reported half-life for Ventfort is Not established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Ventfort?

Ventfort has the sequence Peptide complex A-3 (mixture; sequence not defined), giving a chain of 2 amino acids. Its molecular formula is C15H23N3O10.

### What peptides are similar to Ventfort?

Compounds most often compared with Ventfort include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/)
- [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/)
- [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)
- [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/)
- [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)
